2023年，第59届美国临床肿瘤学会（ASCO）年会将于美国芝加哥当地时间6月2日至6日举行。4月26日，ASCO官网已公布了本次会议的日程和摘要题目。
【肿瘤资讯】整理了口头摘要专场（Oral Abstract Session）、临床科学研讨会（Clinical Science Symposium）、摘要速递专场（Rapid Abstract Session）、全体大会（Plenary Session）、教育专场：摘要更新速递（Plenary Series: Rapid Abstract Updates）及壁报交流专场（Poster Discussion Session）的消化肿瘤研究，与读者分享。
口头摘要专场——消化肿瘤：胃食管癌及肝胆胰肿瘤
摘要号：4000
ATTRACTION-5试验：纳武利尤单抗联合化疗作为病理学Ⅲ期（pStage Ⅲ）胃或胃食管交界处（G/GEJ）肿瘤的术后辅助治疗
ATTRACTION-5: A phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage III (pStage III) gastric or gastroesophageal junction (G/GEJ) cancer
讲者: Masanori Terashima, MD, PhD, FACS | Shizuoka Cancer Center, Devision of Gastric Surgery
摘要号：4001
围手术期PD-1抗体特瑞普利单抗联合SOX/XELOX化疗vs.单纯SOX/XELOX化疗治疗局部晚期胃或胃食管交界处肿瘤：来自前瞻性、随机、开放标签的Ⅱ期试验
Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial
讲者: 中国广东，中山大学肿瘤防治中心 袁庶强，MD
摘要号：4002
Ⅲ期IMbrave050试验的疗效、安全性和患者报告结果(PRO)：阿替利珠单抗(atezo)+贝伐珠单抗(bev)辅助治疗vs.主动监测接受切除或消融后疾病复发高风险的肝细胞癌（HCC）患者
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation
讲者：Masatoshi Kudo, MD, PhD | Kindai University Hospital
摘要号：4003
帕博利珠单抗(pembro)联合吉西他滨和顺铂(gem/cis)vs.安慰剂联合gem/cis 治疗晚期胆道恶性肿瘤（BTC）：3期KEYNOTE-966研究的健康相关生活质量 (HRQoL)分析
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).
讲者：Changhoon Yoo, MD, PhD | Asan Medical Center, University of Ulsan College of Medicine
摘要号：4004
3期HIMALAYA研究：使用tremelimumab(T)联合度伐利尤单抗(D)治疗不可切除肝细胞癌(uHCC)的免疫介导不良事件(imAE)的结果分析
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
讲者：George Lau, MD | Humanity and Health Clinical Trial Center, Humanity and Health Medical Group
摘要号：LBA4005
短期新辅助FOLFIRINOX vs.前期手术治疗可切除胰头癌：一项多中心随机Ⅱ期试验 (NORPACT-1)
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1)
讲者：Knut Jørgen Labori, MD PhD | Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo
摘要号：4006
脂质体伊立替康 + 5-氟尿嘧啶/亚叶酸 + 奥沙利铂(NALIRIFOX)vs.白蛋白结合型紫杉醇 + 吉西他滨治疗初治转移性胰腺导管腺癌(mPDAC)患者：3期NAPOLI 3试验的12个月及18个月生存率分析
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
讲者：Eileen Mary O'Reilly, MD | Memorial Sloan Kettering Cancer Center
摘要号：4007
Tucatinib和曲妥珠单抗治疗既往经治的HER-2阳性转移性胆道恶性肿瘤 (SGNTUC-019)：一项 2期篮子研究
Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study.
讲者：Yoshiaki Nakamura, MD, PhD | National Cancer Center Hospital Japan East
摘要号：4008
关键期(Ph)2b期HERIZON-BTC-01研究的结果：Zanidatamab治疗既往经治的HER-2扩增胆道恶性肿瘤(BTC)
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).
讲者：Shubham Pant, MD | MD Anderson Cancer Center
口头摘要专场——消化肿瘤：结直肠癌及肛门癌
摘要号：3500
FOLFOXIRI 联合贝伐珠单抗和阿替利珠单抗作为不可切除转移性结直肠癌 (mCRC)的前期治疗：Ⅱ期随机 AtezoTRIBE 研究的更新及总体生存结果
FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study
讲者：Carlotta Antoniotti, MD, PhD | Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana
摘要号：3501
德曲妥珠单抗(T-DXd)用于HER-2过表达/扩增(HER2+)转移性结直肠癌 (mCRC)患者(pts)：多中心、随机、2期 DESTINY-CRC02研究的主要结果
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study
讲者：Kanwal Pratap Singh Raghav, MBBS | The University of Texas MD Anderson Cancer Center
摘要号：LBA3503
评估新辅助化疗vs.标准治疗在局部晚期结肠癌患者疗效的Ⅲ期随机临床试验：NeoCol试验
Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial
讲者：Lars Henrik Jensen, MD, PhD | Danish Colorectal Cancer Center South, University Hospital of Southern Denmark, Vejle Hospital
摘要号：LBA3504
在局部晚期直肠癌患者中使用全程新辅助治疗mFOLFIRINOX vs.术前放化疗：PRODIGE 23 III 期试验（一项 UNICANCER GI 主导的试验）的 7 年结果
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial
讲者：Thierry Conroy, MD | Institut de Cancérologie de Lorraine
摘要号：3505
新辅助mFOLFOX6联合或不联合放疗vs.氟尿嘧啶联合放疗治疗局部晚期直肠癌的长期结果：一项多中心、随机Ⅲ期试验
Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial
讲者：中国广东，中山大学附属第六医院 张剑威，MD
摘要号：3506
SCRUM-Japan GOZILA研究：Neo RAS野生型转移性结直肠癌
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
讲者：Hiroki Osumi, MD, PhD | Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research
摘要号：3507
III 期 FIRE-4 研究 (AIO KRK-0114)：基线液体活检结果在FOLFIRI/西妥昔单抗一线治疗组织RAS-WT mCRC患者疗效的影响
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC
讲者：Sebastian Stintzing, MD | Medical Department, Division of Hematology, Oncology, and Cancer Immunology (CCM), Charité Universitätsmedizin Berlin
摘要号：3508
panitumumab在左半结肠肿瘤、MSS/MSI-L和RAS/BRAF WT患者的疗效：Ⅲ期 PARADIGM 试验的生物标志物研究
Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial
讲者：Kentaro Yamazaki, MD, PhD | Division of Gastrointestinal Oncology, Shizuoka Cancer Center
全体大会
摘要号：LBA2
随机Ⅲ期PROSPECT试验：新辅助放化疗vs.新辅助FOLFOX化疗，联合选择性放化疗，随后行全直肠系膜切除术 (TME) 治疗局部晚期直肠癌 (LARC) (Alliance N1048)
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048)
讲者：Deborah Schrag, MD, FASCO, MPH | Memorial Sloan Kettering Cancer Center
教育专场：摘要更新速递
摘要更新：405736
Abstract#405736更新： Zolbetuximab联合Capox一线治疗Claudin-18.2阳性(CLDN18.2+)/HER-2阴性局部晚期(LA)或转移性胃或胃食管交界处腺癌(mG/GEJ)：3期Glow试验的主要结果
Updates on Abstract 405736: Zolbetuximab + Capox in 1L Claudin-18.2+ (CLDN18.2+)/HER2− Locally Advanced (LA) or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results from Glow
讲者：中国广东，中山大学肿瘤防治中心 徐瑞华，MD, PhD
临床科学研讨会：肝胆肿瘤的靶向及TIGHT
摘要号：4009
ReFocus试验剂量递增更新结果：高选择性FGFR2抑制剂 RLY-4008在胆管癌及其他实体瘤中的首次人体研究
Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors
讲者：Mitesh J. Borad, MD | Mayo Clinic Arizona
摘要号：4010
MORPHEUS-liver研究的结果：Ⅰb/Ⅱ期随机评估tiragolumab(tira)联合阿替利珠单抗(atezo)和贝伐珠单抗(bev)治疗不可切除局部晚期或转移性肝细胞癌(uHCC)患者
Results from the MORPHEUS-liver study: Phase Ib/II randomized evaluation of tiragolumab (tira) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)
讲者：Richard S. Finn, MD | University of California Los Angeles
摘要号：4011
nanvuranlat治疗预处理的晚期难治性胆道恶性肿瘤(BTC)的双盲、安慰剂对照2期研究的亚组分析：具有高LAT1表达和对nanvuranlat有治疗反应的患者亚组
Subgroup analysis of double-blind, placebo-controlled Ph. 2 study of nanvuranlat in treatment of pre-treated, advanced, refractory biliary tract cancer (BTC): Patients with high LAT1 expression and response to nanvuranlat
讲者：Masafumi Ikeda, MD, PhD | Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
临床科学研讨会：早发型结直肠癌的分子基础
摘要号：3509
早发型结直肠癌(CRC)患者的转录代谢谱分析
Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients
讲者：Deepak Vadehra, DO | Roswell Park Comprehensive Cancer Center
摘要号：3510
早发型与平均年龄发病的结直肠腺癌的代谢组学差异
Metabolomic differences in young-onset versus average-onset colorectal adenocarcinoma
讲者：Thejus Jayakrishnan, MD | Taussig Cancer Institute
摘要号：3511
早发型与晚发型结直肠癌基因组改变的评估
Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer
讲者：Eric Michael Lander, MD | Division of Hematology/Oncology, Vanderbilt University Medical Center
壁报交流专场——胃食管癌及肝胆胰肿瘤
摘要号：4014 | Poster Bd #334
KEYNOTE-859研究：帕博利珠单抗联合化疗治疗晚期HER-2阴性胃或胃食管交界处(G/GEJ)肿瘤——特定方案下基于PD-L1水平选择适宜人群的结果
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
讲者：Sun Young Rha, MD | Yonsei Cancer Center, Yonsei University Health System
摘要号：4027| Poster Bd #335
DKN-01联合替雷利珠单抗 + 化疗作为晚期胃或胃食管交界处腺癌（G/GEJA)患者的一线(1L)治疗的2期研究(DisTinGuish)
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA）
讲者：Samuel J Klempner, MD | Mass General Cancer Center
摘要号：4015| Poster Bd #336
信迪利单抗和安罗替尼联合吉西他滨加顺铂(GemCis)作为晚期胆道恶性肿瘤(BTC)患者(pts)一线治疗：2期随机、开放标签、多中心SAGC研究
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC
讲者：中国浙江，浙江省肿瘤医院 应杰儿
摘要号：4016| Poster Bd #337
晚期胆囊癌(GBC)一线化疗(CT)后巩固化放疗(CTRT)vs.观察：RACE-GB随机研究
A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study
讲者：Sushma Agrawal, MD | SGPGI
摘要号：4017| Poster Bd #338
多中心、开放标签、随机Ⅱ期GECCOR-GB试验：评估吉西他滨加顺铂（GC) 和卡培他滨联合卡培他滨同步放疗(CAPE-RT)辅助治疗胆囊腺癌(GBC)手术患者
A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial
讲者：Anant Ramaswamy, DM | Tata Memorial Hospital (HBNI)
摘要号：4018| Poster Bd #339
早发型胰腺癌的临床和基因组特征
Clinical and genomic characterization of early-onset pancreatic cancer
讲者：Florian Castet, MD | Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus
摘要号：4019| Poster Bd #340
随机 III 期多中心 BILCAP临床试验：探究肝内胆管癌(iCCA)患者的癌症驱动基因及其他潜在可靶向的基因突变
Investigating alterations in cancer driver genes and other potentially targetable mutations in patients with intrahepatic cholangiocarcinoma (iCCA) treated on the randomised phase III multicentre BILCAP clinical trial.
讲者：Valerie Elizabeth Crolley, MBBS, MRCP | UCL-University College London (United Kingdom)
摘要号： 4020| Poster Bd #341
经治的KRAS突变型胰腺癌大有不同：KRAS G12D亚型及其生存结果
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome
讲者：Bach Ardalan, MD | Sylvester Comprehensive Cancer Center
摘要号： 4021| Poster Bd #342
随机、开放标签 2 期FOOTPATH研究：脂质体伊立替康 + 5-FU + 亚叶酸 (NAPOLI)vs.序贯NAPOLI和mFOLFOX6 vs.吉西他滨/白蛋白结合型紫杉醇治疗初治转移性胰腺癌(mPDAC)
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC)
讲者：Benedikt Westphalen, MD | Department of Medicine III and Comprehensive Cancer Center (CCC Munich LMU), University Hospital, LMU Munich, Munich, Germany
摘要号：4022| Poster Bd # 343
18F-FDG PET/CT 和 68Ga-DOTA-TOC同步成像在胃肠胰腺神经内分泌肿瘤 (GEPNENs) 中应用的前瞻性评估：PETNET 研究
Prospective evaluation of the utility of concurrent 18F-FDG PET/CT and 68Ga-DOTA-TOC imaging in gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): The PETNET study
讲者：Joao Paulo Solar Vasconcelos, MD | BC Cancer, Vancouver Cancer Centre
摘要号：4023| Poster Bd #344
超越米兰标准：FOLFOX新辅助肝动脉灌注化疗可改善可切除的BCLC A/B期肝细胞癌患者的预后——一项多中心、3期、随机、对照临床试验
Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial
讲者：中国广东，中山大学肿瘤防治中心 韦玮M.D, PH.D
壁报讨论专场——消化肿瘤：结直肠癌及肛门癌
摘要号：3512| Poster Bd #212
曲氟尿苷替吡嘧啶+贝伐珠单抗vs.卡培他滨+贝伐珠单抗的总生存期结果：来自 3 期 SOLSTICE 研究的结果
Overall survival results for trifluridine/tipiracil plus bevacizumab vs capecitabine plus bevacizumab: Results from the phase 3 SOLSTICE study
讲者：Thierry Andre, MD | Hôpital Saint-Antoine
摘要号：3513| Poster Bd #213
Sotorasib (Soto) 联合 panitumumab (Pmab) 和 FOLFIRI 治疗既往经治的KRAS G12C突变转移性结直肠癌(mCRC)：CodeBreaK 101 1b 期安全性和有效性分析
Sotorasib (Soto) plus panitumumab (Pmab) and FOLFIRI for previously treated KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreaK 101 phase 1b safety and efficacy
讲者：David S. Hong, MD | University of Texas MD Anderson Cancer Center
摘要号：3514| Poster Bd #214
WNT 通路Porcupine抑制剂CGX1321的1 期研究和CGX1321 + 帕博利珠单抗(pembro)在晚期胃肠道 (GI)肿瘤患者(pts)中的1b期研究
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.
讲者：Marios Giannakis, MD, PhD | Dana-Farber Cancer Institute
摘要号：3515| Poster Bd #215
肝复发高风险患者结直肠癌肝转移切除术后肝动脉化疗：一项多中心随机Ⅱ期试验(PRODIGE 43 - PACHA-01)
Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).
讲课：Maximiliano Gelli, MD, PhD | Gustave Roussy
摘要号：3516| Poster Bd #216
结直肠癌肝转移切除术后患者接受或不接受氟尿苷肝动脉输注的辅助全身化疗 (HARVEST)：一项前瞻性随机对照试验
Adjuvant systemic chemotherapy with or without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastases resection (HARVEST): A prospective, randomized controlled trial
讲者：中国广东，中山大学肿瘤防治中心 李宇红
摘要号：3517| Poster Bd #217
同步转移性结直肠癌患者原发肿瘤的前期姑息性切除与不切除：荷兰结直肠癌组(DCCG)主导的随机3期CAIRO4研究
Upfront palliative resection of primary tumor versus no resection in patients with synchronous metastatic colorectal cancer: The randomized phase 3 CAIRO4 study of the Dutch Colorectal Cancer Group (DCCG).
讲者：Miriam Koopman, MD, PhD | Department of Medical Oncology, University Medical Center Utrecht, Utrecht University
摘要号：3518| Poster Bd #218
在CRS-HIPEC治疗结直肠癌腹膜转移后，用224镭标记微粒腹腔内治疗后15 个月的安全性和有效性数据
15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.
讲者：Stein G Larsen, PhD | Norwegian Radium Hospital
摘要号：3519| Poster Bd #219
极低部位临床分期(c)T3直肠癌接受新辅助化疗(NAC)后全直肠系膜切除术(TME)及辅助化疗vs. TME后辅助化疗：多中心、随机、开放标签、2期/ 3期试验(NAIR)
Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR): A multicenter, randomized, open-label, phase 2/3 trial.
讲者：Yuichiro Tsukada, MD, PhD | Department of Colorectal Surgery, National Cancer Center Hospital East
摘要号：3520| Poster Bd # 220
接受全程新辅助治疗的直肠癌患者的持续性器官保留：OPRA试验的长期结果
Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial
讲者：Floris S Verheij, BSc | Memorial Sloan Kettering Cancer Center
摘要号：3521| Poster Bd #221
循环肿瘤DNA动力学可作为接受根治手术的结直肠癌患者早期复发的预测因子：CIRCULATE-Japan主导的GALAXY 研究最新结果
Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updated results from GALAXY study in the CIRCULATE-Japan.
讲者：Eiji Oki, MD, PhD, FACS | Kyushu University
摘要号：3522| Poster Bd #222
结直肠癌(CRC)监测期间基于ctDNA的阳性微小残留病灶检测与未诊断的伴随影像学复发的关联：来自MD Anderson INTERCEPT流程的结果
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program
讲者：Arvind Dasari, MD, MS | Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center
摘要号：3523| Poster Bd #223
来自 PETACC-8 和 IDEA France 试验的 III 期结肠癌肿瘤微环境和细胞周期转录组学特征的复发预测模型
Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials
讲者：Claire Gallois, MD | Institut du Cancer Paris CARPEM, APHP, Digestive Oncology Department, APHP.Centre - Université Paris Cité, Hôpital Européeen G. Pompidou
（本文依照报告日期和出场排序整理，如有错误或遗漏，敬请留言指正。）
https://meetings.asco.org/meetings/2023-asco-annual-meeting/299/program-guide/scheduled-sessions
排版编辑：肿瘤资讯-Bree
苏公网安备32059002004080号
